Aratana Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Presentation Scheduled for Friday, September 27 at 10:30 a.m. ET

KANSAS CITY, Kan. and BOSTON, Sept. 27, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets (pet therapeutics), today announced that it will present at the BioCentury's NewsMakers in the Biotech Industry Conference to be held September 27, 2013, at the Millennium Broadway Hotel in New York City.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences. 

Event:


BioCentury's NewsMakers in the Biotech Industry Conference

Date: 


Friday, September 27, 2013 

Time: 


10:30 a.m. (Eastern Time) 

Location:


Millennium Broadway Hotel 145 W. 44th Street; New York

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694  

SOURCE Aratana Therapeutics